---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-011213"
form_type: "8-K"
ticker: "NDRA"
cik: "0001681682"
company_name: "ENDRA Life Sciences Inc."
filed_at: "2024-08-28T23:59:59+00:00"
generated_at: "2026-05-31T07:11:37.884548+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ENDRA Life Sciences gets Nasdaq extension to Nov 20, 2024 to regain $1 bid price; 91% of Series B warrants exercised

## Summary
- Nasdaq Hearings Panel granted extension until November 20, 2024 to regain compliance with $1.00 minimum bid price for 10 consecutive trading days.
- Company is evaluating options to evidence compliance; no immediate effect on listing or trading of NDRA common stock.
- 91% of Series B warrants from June 2024 public offering exercised, resulting in issuance of 15,831,864 shares of common stock.
- Total outstanding common shares increased to 17,280,655 as of August 28, 2024.

## SEC filing metadata
- accession: 0001654954-24-011213
- form_type: 8-K
- ticker: NDRA
- cik: 0001681682
- company_name: ENDRA Life Sciences Inc.
- filed_at: 2024-08-28T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681682/000165495424011213/0001654954-24-011213-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681682/000165495424011213/endra_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-011213
- JSON: https://secwatch.observer/filing/0001654954-24-011213.json
- Plain text: https://secwatch.observer/filing/0001654954-24-011213.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.